Overview
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Eligibility
Key Inclusion Criteria:
- Body weight greater than or equal to (≥)45 kilogram (kg)
- Body mass index (BMI) ≥18 to less than (\<) 40 kilogram per meter square (kg/m\^2)
- Diagnosis of diabetes mellitus type 1 or type 2 and with glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN for at least 1 year
- Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period
Key Exclusion Criteria:
- More than 3 missing daily NPRS scores during the 7-day Baseline Period
- Received Journavx within 30 days of study drug dosing
- Any sensory abnormality (excluding DPN) as pre-specified in the protocol
Other protocol defined Inclusion/Exclusion criteria may apply.